iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market
iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has completed a $1.75 million private placement of common stock and pre-funded warrants. The company issued 1,559,828 shares at $1.122 per share, priced at-the-market under Nasdaq rules.
Of the net proceeds, $500,000 will be allocated to marketing and advertising services through IR Agency LLC, with the remainder supporting working capital and general corporate purposes. WestPark Capital served as the exclusive placement agent for the offering, which closed on August 4, 2025.
iSpecimen (Nasdaq: ISPC), un mercato online per biospecimen, ha completato un collocamento privato di 1,75 milioni di dollari in azioni ordinarie e warrant prefinanziati. La societ脿 ha emesso 1.559.828 azioni a 1,122 dollari per azione, prezzo conforme alle regole di Nasdaq.
Dei proventi netti, 500.000 dollari saranno destinati a servizi di marketing e pubblicit脿 tramite IR Agency LLC, mentre il resto sar脿 utilizzato per il capitale circolante e scopi aziendali generali. WestPark Capital ha agito come agente di collocamento esclusivo per l'offerta, chiusa il 4 agosto 2025.
iSpecimen (Nasdaq: ISPC), un mercado en l铆nea de biospec铆menes, ha completado una colocaci贸n privada de 1,75 millones de d贸lares en acciones comunes y warrants prefinanciados. La compa帽铆a emiti贸 1.559.828 acciones a 1,122 d贸lares por acci贸n, precio conforme a las normas de Nasdaq.
De los ingresos netos, 500.000 d贸lares se destinar谩n a servicios de marketing y publicidad a trav茅s de IR Agency LLC, y el resto apoyar谩 el capital de trabajo y fines corporativos generales. WestPark Capital actu贸 como agente exclusivo de colocaci贸n para la oferta, que se cerr贸 el 4 de agosto de 2025.
iSpecimen (雮橃姢雼�: ISPC)電� 氚旍澊鞓れ儤頂� 鞓澕鞚� 毵堨紦頂岆爤鞚挫姢鞚措┌, 175毵� 雼煬 攴滊鞚� 靷欤检嫕 氚� 靹犽偐 鞗岆煱韸� 氚滍枆鞚� 鞕勲頄堨姷雼堧嫟. 須岇偓電� 1,559,828欤�毳� 欤茧嫻 1.122雼煬鞐� 氚滍枆頄堨溂氅�, 鞚措姅 雮橃姢雼� 攴滌爼鞐� 霐半ジ 鞁滉皜鞛呺媹雼�.
靾滌垬鞚� 欷� 50毵� 雼煬電� IR Agency LLC毳� 韱淀暅 毵堨紑韺� 氚� 甏戧碃 靹滊箘鞀れ棎 頃犽嫻霅橂┌, 雮橂ǜ歆�電� 鞖挫爠鞛愲掣 氚� 鞚茧皹 旮办梾 氇╈爜鞐� 靷毄霅╇媹雼�. WestPark Capital鞚� 鞚措矆 瓿惦鞚� 霃呾爯 欤缄磤靷 彀胳棳頄堨溂氅�, 2025雲� 8鞗� 4鞚检棎 毵堦皭霅橃棃鞀惦媹雼�.
iSpecimen (Nasdaq : ISPC), une place de march茅 en ligne pour les biosp茅cimens, a finalis茅 un placement priv茅 de 1,75 million de dollars en actions ordinaires et bons de souscription pr茅financ茅s. La soci茅t茅 a 茅mis 1 559 828 actions 脿 1,122 dollar par action, prix conforme au march茅 selon les r猫gles du Nasdaq.
Sur le produit net, 500 000 dollars seront allou茅s aux services de marketing et de publicit茅 via IR Agency LLC, le reste soutenant le fonds de roulement et les besoins g茅n茅raux de l'entreprise. WestPark Capital a agi en tant qu'agent de placement exclusif pour cette op茅ration, qui s'est cl么tur茅e le 4 ao没t 2025.
iSpecimen (Nasdaq: ISPC), ein Online-Marktplatz f眉r Biospezimen, hat eine Privatplatzierung von 1,75 Millionen US-Dollar in Stammaktien und vorfinanzierten Optionsscheinen abgeschlossen. Das Unternehmen gab 1.559.828 Aktien zu 1,122 US-Dollar pro Aktie aus, der Preis entsprach dem Markt gem盲脽 den Nasdaq-Regeln.
Von den Nettoerl枚sen werden 500.000 US-Dollar f眉r Marketing- und Werbedienstleistungen 眉ber IR Agency LLC verwendet, der Rest dient dem Betriebskapital und allgemeinen Unternehmenszwecken. WestPark Capital war als exklusiver Platzierungsagent f眉r das Angebot t盲tig, das am 4. August 2025 abgeschlossen wurde.
- Secured $1.75 million in additional funding through private placement
- Strategic allocation of $500,000 for marketing and advertising to drive growth
- Placement priced at-the-market, indicating fair market valuation
- Potential dilution for existing shareholders from issuance of 1,559,828 new shares
- Need for additional capital suggests potential cash flow concerns
Insights
iSpecimen secured $1.75M through at-market private placement, with significant portion earmarked for marketing amid likely cash constraints.
iSpecimen has closed a
The pricing "at-the-market" indicates the company couldn't command a premium, reflecting current market sentiment toward the stock. WestPark Capital served as the exclusive placement agent, though their fees weren't specified in the release. These fees will further reduce the net proceeds available to the company.
This financing appears to be a stopgap measure rather than a transformative capital injection. For context, a biotech marketplace like iSpecimen typically requires substantial capital to scale operations, enhance platform capabilities, and expand its provider network. The modest size of this raise suggests the company may need additional financing in the near future if its operational runway is limited.
The use of a private placement rather than a public offering indicates the company likely found it more efficient to target accredited investors directly. The registration rights agreement with investors shows the company's commitment to providing future liquidity for these shares, which is a standard practice to make private placements more attractive to investors.
WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (鈥渋Specimen鈥� or the 鈥淐ompany鈥�), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately
In connection with the offering, the Company issued 1,559,828 shares of common stock (or pre-funded warrants to purchase shares of common stock) at a purchase price of
The offering closed on August 4, 2025.
WestPark Capital, Inc. acted as the exclusive placement agent in connection with the offering.
Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (the "SEC").
The securities described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit听.听
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 鈥渇orward-looking statements.鈥� These statements include, but are not limited to, statements concerning the development of our company. The words 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions and the Company鈥檚 ability to satisfy the closing conditions related to the Offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 鈥淩isk Factors鈥� section of the Company鈥檚 Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
听
FAQ
What is the size and price of iSpecimen's (ISPC) August 2025 private placement?
How will iSpecimen (ISPC) use the proceeds from its private placement?
Who served as the placement agent for iSpecimen's (ISPC) private placement?
What is iSpecimen's (ISPC) core business model?
Will the new shares from ISPC's private placement be registered?
